KINGWORLD MEDICINES GROUP LIMITED

金活醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 01110)

ESTIMATE FOR ANNUAL RESULTS OF 2025

This announcement is made by Kingworld Medicines Group Limited (the "**Company**" and together with its subsidiaries, the "**Group**") pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2025 (the "**Year**") and the information currently available to the Board, the Group is expected to record a profit attributable to owners of the Company for the second half of 2025 from a loss of approximately RMB5.4 million for the first half of 2025. However, the Group is still expected to record a decrease in the profit attributable to owners of the Company by approximately 70% to 75% for the Year as compared to approximately RMB41.6 million for the year ended 31 December 2024 (the "**Previous Year**").

The Board considers that the decrease in the profit attributable to owners of the Company was mainly due to the following factors:

(i) the decrease in the gross profit from distribution of imported branded pharmaceutical and healthcare products in China by approximately 15% to 20%, primary due to a slowdown in the demand for the related products in the market; and

(ii) the decrease in promotion fee income by approximately 40% to 45% for the Year as compared to approximately RMB12.6 million for the Previous Year, primary due to a reduction in the number of promotion events.

Information contained in this announcement is based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the Year and information currently available to the Board. Information in this announcement has not been reviewed nor audited by the auditors of the Company, nor reviewed by the audit committee of the Company. The actual results of the Group for the Year are subject to adjustment and may differ from the information disclosed herein. Shareholders and potential investors are advised to read carefully the results announcement of the Group for the Year, which is expected to be published by the Company on 31 March 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Kingworld Medicines Group Limited
Zhao Li Sheng
Chairman

Hong Kong, 24 March 2026

As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San and Mr. Zhou Xuhua, the independent non-executive Directors are Mr. Duan Jidong, Mr. Wong Cheuk Lam and Dr. Chu Xiaoping.

* *For identification purpose only*